Lucitanib

Lucitanib

Clinical data
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	Investigational
Pharmacokinetic data
Biological half-life	31–40 hrs
Identifiers
IUPAC name 6-({7-[(1-Aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl}oxy)-N-methyl-1-naphthamide
Synonyms	CO-3810, E-3810
CAS Number	1058137-23-7
PubChem CID	25031915
ChemSpider	28189586
UNII	PP449XA4BH
ChEBI	CHEBI:65209
ChEMBL	CHEMBL2180605
Chemical and physical data
Formula	C26H25N3O4
Molar mass	443.50 g·mol−1
3D model (JSmol)	Interactive image
SMILES CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC
InChI InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30) Key:CUDVHEFYRIWYQD-UHFFFAOYSA-N

Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours including metastatic breast cancer. It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta.